About Event

Having been on the injectable device development journey with leading biopharma over the past 13 years, we have witnessed parenteral evolution from prefilled syringe to autoinjector, to connected devices; as well as the regulatory requirements transitioning from combination products to EU MDR, to the latest human factors and EPR.

With increased emphasis on patient centricity, high volume and long-acting injectables, injectable device engineers are faced with a new set of challenges. The 13th Injectables Summit was the definitive forum that brought together different disciplines in the Device Design, Engineering, HFE and Quality experts under one roof to share lessons learned and inspire each other to strive towards the common goal of delivering quality drugs to patients faster.

The 3-day summit provided attendees with clarity on streamlining end-to-end device development journeys, route to global market access with regulatory compliance in mind.

Supported by industry leaders from BioMarin, Takeda, Gilead, Sanofi and more, attendees heard the latest case studies in device development across 3 packed days to accelerate their injectable device’s speed to market:

  • Learnt how to integrate the results of both formative and validation Human Factors Studies into your device development from industry experts in usability and device development
  • Heard from BioMarin in how to develop an injectable device with the MDR in mind
  • Developed and streamlined their cross-functional collaboration to improve the speed-to-clinic of their injectable device
  • Gilead shared how they enable a fast scale-up of the injectable device development via a transferable automated manufacture process
  • As sustainability questions really begin to develop traction in the injectable device space, industry experts discussed new strategies to improve the sustainability profile of injectable device development

Hear What Your Peers Have to Say:

''The summit allowed for great opportunities to meet other attendees and network. The agenda and topics were well chosen.''

Director, Gilead

''High quality speakers, relevant topics and high-level engagement from audience and speakers.''

Head of Device Innovation, GSK

''Quality presenters on relevant topics for devices and digital health.''

Associate Director of Device & Digital Health, Merck